BluGlass partners with global photonics leader Coherent on novel GaN device
BluGlass Limited (ASX: BLG) has entered into an early-stage collaboration with global photonics leader Coherent Corp (NYSE: COHR) to co-develop a novel gallium nitride (GaN)-based device targeting scientific and medical markets. The collaboration is valued at approximately A$286k (US$200k) and involves an initial feasibility study expected to run for three to five months, evaluating the compatibility of both companies’ proprietary processes.
When big ASX news breaks, our subscribers know first
What the collaboration involves
Each party brings distinct capabilities to the joint effort:
- BluGlass: Proprietary GaN epitaxial growth, semiconductor laser development, and end-to-end manufacturing spanning epitaxy through to testing.
- Coherent: Photonics engineering leadership, advanced manufacturing, commercialisation capabilities, and global market access.
Under the agreement, the companies will jointly evaluate device architectures and manufacturing techniques to enable high-performance visible-wavelength lasers for scientific instrumentation and medical applications. Initial development discussions have already commenced, covering device architecture options, epitaxial structure designs, and process integration.
BluGlass CEO Jim Haden commented on the significance of the partnership:
Jim Haden, CEO, BluGlass
“Coherent’s decision to collaborate with BluGlass is a strong vote of confidence in our GaN epitaxy and laser capabilities, reinforcing our growing industry reputation for developing differentiated technology solutions to support next-generation applications. While the initial phase of this collaboration focuses on advancing a novel device architecture, it has the longer-term potential to address high-value opportunities in scientific and medical applications. The collaboration with this industry leader expands our GaN laser portfolio and, more importantly, extends our reach into key scientific and medical markets that demand precision photonic performance.”
Understanding GaN laser technology and why it matters
Gallium nitride (GaN) laser diodes are semiconductor devices that produce light in the visible-wavelength spectrum, typically blue, violet, and green. This visible-light output makes them particularly suited to scientific instrumentation and medical applications, where precision, power, and beam quality are critical performance requirements.
Manufacturing GaN lasers is technically demanding. BluGlass is one of only a handful of companies globally with the capability to produce GaN lasers end-to-end, covering the full process from epitaxial growth through device fabrication and testing. That scarcity gives the company a strategically differentiated position within the global photonics supply chain.
A key part of BluGlass’s manufacturing edge is its proprietary remote plasma chemical vapour deposition (RPCVD) process, a low-temperature, low-hydrogen technique that enables differentiated epitaxial layer quality in GaN structures. Coherent’s decision to enter this collaboration suggests the company views BluGlass’s RPCVD-based process as commercially relevant and technically compatible with its own advanced manufacturing platform.
BluGlass’s world-record GaN laser output of 1.9W peak single spatial mode at 450nm, independently verified by the University of California, Santa Barbara, represents the kind of measurable technical differentiation that makes the company an attractive co-development partner for a platform-scale photonics company like Coherent.
For investors, GaN laser technology spans markets including defence, biomedical, and scientific instrumentation, sectors generally characterised by premium pricing and long-term customer relationships.
Strategic significance and what comes next
A collaboration with Coherent, a NYSE-listed company operating in more than 20 countries with a vertically integrated photonics technology platform, signals meaningful external validation of BluGlass’s capabilities within the global GaN laser ecosystem. For an ASX-listed company of BluGlass’s scale, securing a co-development agreement with a photonics company of this profile is a notable step.
The key parameters of the collaboration are summarised below:
| Detail | Specifics |
|---|---|
| Partner | Coherent Corp (NYSE: COHR) |
| Deal Value | ~A$286k (US$200k) |
| Duration | Three to five months (feasibility study) |
| Target Markets | Scientific instrumentation, medical applications |
| Scope | Joint evaluation of device architectures and manufacturing techniques for high-performance visible-wavelength lasers |
BluGlass has described this as an early-stage collaboration, and it is important to note that the feasibility study determines process compatibility only. A commercial outcome is not guaranteed at this stage. The study’s purpose is to assess whether both companies’ proprietary processes can be integrated effectively to produce the target device architecture.
If the feasibility study yields positive results, BluGlass would be positioned to pursue a deeper commercial relationship with one of the world’s largest and most established photonics companies, potentially opening access to Coherent’s global customer base across scientific and medical markets.
For investors exploring the funding position and pipeline context behind these commercial programmes, our detailed coverage of BluGlass’s $8M capital raise sets out the 29-opportunity project pipeline exceeding US$100 million in total value, the 97% revenue CAGR since FY21, and the strategic rationale for scaling GaN laser manufacturing capacity.
Get ASX Tech News Before the Market Moves
Big News Blast delivers FREE breaking ASX tech announcements directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market on high-impact news. Click the “Free Alerts” button at StockWire X to start receiving alerts today.